The expanded authorizations came two weeks after Novavax submitted to the FDA its application for an EUA for its own booster dose for adults ages 18 and older. The expanded EUAs will likely expand the gap in doses administered between Novavax and three more established COVID-19 vaccine rivals—not only Pfizer/BioNTech and Moderna, but also Johnson & Johnson (J&J . . .
See More on the Edge
Continue reading this article and more
with a GEN Edge subscription
The post StockWatch: Novavax Hits 52-Week Low as Rivals Win FDA Omicron Booster OKs appeared first on GEN – Genetic Engineering and Biotechnology News.
